8-K: Evoke Pharma Q2 Sales Soar 47% on GIMOTI Demand

Evoke Pharma reported a 47% year-over-year increase in GIMOTI net product sales for Q2 2025, reaching $3.8 million, and confirmed its full-year 2025 revenue guidance of $16 million.

Summary

• Net product sales for the second quarter of 2025 were $3.8 million, a 47% increase compared to $2.6 million in Q2 2024.
• Net product sales for the six months ended June 30, 2025, were $6.8 million, up from $4.3 million in the same period of 2024.
• Net loss for Q2 2025 was $1.6 million, or ($0.62) per share, compared to $1.3 million, or ($0.93) per share, in Q2 2024.
• Net loss for the six months ended June 30, 2025, was $2.9 million, or ($1.13) per share, compared to $2.8 million, or ($2.69) per share, in the same period of 2024.
• Selling, general, and administrative expenses increased to $5.1 million in Q2 2025 from $3.7 million in Q2 2024, primarily due to higher profit-sharing with EVERSANA and professional fees.
• Total operating expenses for Q2 2025 were $5.3 million, up from $3.8 million in Q2 2024.
• Cash and cash equivalents stood at $12.1 million as of June 30, 2025.
• Full-year 2025 net product sales guidance of approximately $16 million was confirmed, representing up to a 60% increase over 2024.

Sentiment

Score: 8

Explanation: The strong year-over-year sales growth of 47% for GIMOTI, coupled with a 20% increase in new prescribers and steady refill rates, indicates robust commercial momentum and increasing market adoption. The confirmation of full-year revenue guidance and an extended cash runway into Q3 2026 provide financial stability and confidence in future operations, despite ongoing net losses. The decrease in net loss per share also signals improving financial efficiency.

Positives

• Net product sales increased 47% year-over-year to $3.8 million in Q2 2025, reflecting expanded pharmacy access and increased physician adoption.
• New prescribers grew 20% year-over-year, indicating continued positive clinical adoption within gastroenterology practices.
• Refill rates remained steady at approximately 70%, suggesting consistent therapeutic benefit for GIMOTI.
• Cash and cash equivalents of $12.1 million as of June 30, 2025, are believed to be sufficient to fund operations into the third quarter of 2026.
• Net loss per share significantly decreased from ($0.93) to ($0.62) in Q2 2025, and from ($2.69) to ($1.13) for the six months ended June 30, 2025.
• Presented real-world safety data for GIMOTI at Digestive Disease Week (DDW) 2025.

Negatives

• The company continues to report a net loss, with $1.6 million in Q2 2025 and $2.9 million for the first six months of 2025.
• Selling, general, and administrative expenses increased significantly to $5.1 million in Q2 2025 from $3.7 million in Q2 2024.
• Total operating expenses increased to $5.3 million in Q2 2025 from $3.8 million in Q2 2024.
• Cash and cash equivalents decreased from $13.6 million at December 31, 2024, to $12.1 million at June 30, 2025.

Risks

• Inability to achieve full-year 2025 net product sales guidance due to potential decreased demand for GIMOTI.
• Challenges in Evoke's and EVERSANA's ability to successfully drive market demand for GIMOTI.
• Potential need for additional financing to support operations, which may not be obtainable.
• Risk of using capital resources sooner than currently expected.
• EVERSANA may terminate the commercial services agreement and loan agreement, requiring repayment of outstanding principal and interest.
• Dependence on third parties for the manufacture of GIMOTI.
• The company is entirely dependent on the success of GIMOTI.
• Risk of inadequate efficacy or unexpected adverse side effects relating to GIMOTI, potentially leading to recalls or product liability claims.
• Challenges in maintaining intellectual property protection for GIMOTI.
• External factors such as macroeconomic conditions, geopolitical volatility, supply chain constraints, and inflationary pressures could negatively impact business.

Future Outlook

Evoke Pharma confirmed its full-year 2025 net product sales guidance of approximately $16 million, which would represent up to a 60% increase over 2024. This guidance is based on current business outlook, including recent trends in prescription growth, refill rates, expanded pharmacy access, and continued adoption of GIMOTI, while also incorporating assumptions around payer reimbursements, conversion rates, and external macroeconomic factors.

Management Comments

• "This quarter's results demonstrate the commercial strength of GIMOTI and the precision of our execution."
• "With 47% year-over-year growth in net product sales and a 20% increase in new prescribers since the second quarter of last year, demand is accelerating from both physicians and patients."
• "Fill rates are improving, and prescriber adoption is broadening across GI practices – signals that GIMOTI is becoming an essential option in the treatment of diabetic gastroparesis."

Industry Context

Evoke Pharma operates in the specialty pharmaceutical sector, focusing on gastrointestinal (GI) disorders. Its primary product, GIMOTI, is a nasal spray formulation of metoclopramide, indicated for diabetic gastroparesis. This condition affects millions globally, and GIMOTI is noted as the only FDA-approved drug in the United States specifically for treating gastroparesis, positioning it uniquely in the market against oral and injectable metoclopramide formulations.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry standard assessment.
• GIMOTI is highlighted as the only FDA-approved drug in the United States for treating gastroparesis, which positions it as a unique offering in its therapeutic area.
• The 47% year-over-year sales growth and 20% increase in new prescribers suggest strong market penetration and adoption within its niche, potentially outperforming general pharmaceutical market growth rates, though specific benchmarks are not provided.

Stakeholder Impact

• Shareholders: Positive impact due to strong sales growth, confirmed revenue guidance, and extended cash runway, potentially leading to increased shareholder value.
• Patients: Continued access to GIMOTI for diabetic gastroparesis, with improving fill rates and broader prescriber adoption.
• Physicians: Increased adoption of GIMOTI as an essential treatment option for diabetic gastroparesis.
• EVERSANA: Higher profit-sharing activity due to increased net product sales, strengthening the commercial partnership.
• Employees: Continued operational stability and growth may positively impact job security and opportunities.

Next Steps

• Continue driving market demand for GIMOTI through expanded pharmacy access and physician adoption.
• Manage operating expenses, particularly selling, general, and administrative costs, in line with sales growth.
• Monitor and adapt to external factors such as macroeconomic conditions, supply chain constraints, and inflationary pressures.

Key Dates

Recommendation

The significant 47% year-over-year growth in GIMOTI net product sales, coupled with a 20% increase in new prescribers and stable 70% refill rates, demonstrates strong commercial traction and increasing market penetration for Evoke's sole product. The company's confirmation of its full-year 2025 revenue guidance of $16 million, representing up to a 60% increase over 2024, signals confidence in continued robust growth. Furthermore, the extended cash runway into Q3 2026 provides a solid financial foundation, mitigating immediate liquidity concerns. While the company remains unprofitable, the improving net loss per share indicates progress towards profitability. The unique market position of GIMOTI as the only FDA-approved drug for gastroparesis in the US provides a competitive advantage. These factors suggest a positive trajectory for the company, making it an attractive 'buy' for investors seeking growth in the specialty pharmaceutical sector.

Keywords

GIMOTI, metoclopramide, diabetic gastroparesis, specialty pharmaceutical, GI disorders, nasal spray, financial results, Q2 2025, Evoke Pharma, EVOK, pharmaceutical sales, drug development